Skip to main content
SpringerLink
Log in

Loss of BAP1 Protein Expression by Immunohistochemistry in the Salivary Duct Carcinoma Component of an Intracapsular Carcinoma ex Pleomorphic Adenoma of the Parotid Gland

  • Case Report
  • Published:
Head and Neck Pathology Aims and scope Submit manuscript

Abstract

Background

BRCA1-associated protein 1 (BAP1) is a tumor suppressor gene that is altered in a variety of neoplasms as well as in BAP1 tumor predisposition syndrome. BAP1 alterations are associated with aggressive behavior in some malignancies and may have treatment implications in future. We present the first documented case of loss of BAP1 protein expression by immunohistochemistry in the salivary duct carcinoma (SDC) component of an intracapsular carcinoma ex pleomorphic adenoma (CXPA) in the context of molecular loss of function of BAP1 in the neoplasm.

Methods

A woman of approximately 55 years of age presented with a deep parotid lobe mass, which was resected and found to be CXPA. BAP1 immunohistochemistry and next-generation sequencing was performed to further characterize the neoplasm.

Results

The neoplasm showed loss of BAP1 protein expression in the SDC component but retention in the residual pleomorphic adenoma (PA). Next-generation sequencing confirmed a BAP1 loss of function alteration in the neoplasm.

Conclusion

This is the first documented case report of BAP1 protein expression loss in the SDC component of a CXPA. Future studies are needed to investigate the relevance of BAP1 alterations in SDC and CXPA, which may have prognostic and treatment implications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Antony J, Gopalan V, Smith RA, Lam AK (2012) Carcinoma ex pleomorphic adenoma: a comprehensive review of clinical, pathological and molecular data. Head Neck Pathol 6(1):1–9. https://doi.org/10.1007/s12105-011-0281-z

    Article  PubMed  Google Scholar 

  2. Bubola J, MacMillan CM, Demicco EG et al (2021) Targeted RNA sequencing in the routine clinical detection of fusion genes in salivary gland tumors. Genes Chromosomes Cancer 60(10):695–708. https://doi.org/10.1002/gcc.22979

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Chau C, van Doorn R, van Poppelen NM et al (2019) Families with BAP1-tumor predisposition syndrome in The Netherlands: path to identification and a proposal for genetic screening guidelines. Cancers. https://doi.org/10.3390/cancers11081114

    Article  PubMed  PubMed Central  Google Scholar 

  4. Dogan S, Ng CKY, Xu B et al (2019) The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Hum Pathol 88:66–77. https://doi.org/10.1016/j.humpath.2019.03.004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. El Hallani S, Udager AM, Bell D et al (2018) Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases. Am J Surg Pathol 42(1):18–27. https://doi.org/10.1097/pas.0000000000000933

    Article  PubMed  PubMed Central  Google Scholar 

  6. Eletr ZM, Wilkinson KD (2011) An emerging model for BAP1’s role in regulating cell cycle progression. Cell Biochem Biophys 60(1–2):3–11. https://doi.org/10.1007/s12013-011-9184-6

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Eletr ZM, Yin L, Wilkinson KD (2013) BAP1 is phosphorylated at serine 592 in S-phase following DNA damage. FEBS Lett 587(24):3906–3911. https://doi.org/10.1016/j.febslet.2013.10.035

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. George TJ, DeRemer DL, Parekh HD et al (2020) Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms including cholangiocarcinoma. J Clin Oncol. https://doi.org/10.1200/JCO.2020.38.4_suppl.TPS591

    Article  PubMed  PubMed Central  Google Scholar 

  9. Griffith CC, Seethala RR, Luvison A, Miller M, Chiosea SI (2013) PIK3CA mutations and PTEN loss in salivary duct carcinomas. Am J Surg Pathol 37(8):1201–1207. https://doi.org/10.1097/PAS.0b013e3182880d5a

    Article  PubMed  Google Scholar 

  10. Griffith CC, Thompson LDR, Assaad A et al (2014) Salivary duct carcinoma and the concept of early carcinoma ex pleomorphic adenoma. Histopathology 65(6):854–860. https://doi.org/10.1111/his.12454

    Article  PubMed  Google Scholar 

  11. Harbour JW, Onken MD, Roberson ED et al (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413. https://doi.org/10.1126/science.1194472

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hassan R, Mian I, Wagner C et al (2020) Phase II study of olaparib in malignant mesothelioma (MM) to correlate efficacy with germline and somatic mutations in DNA repair genes. J Clin Oncol 38(15):9054–9054. https://doi.org/10.1200/JCO.2020.38.15_suppl.9054

    Article  Google Scholar 

  13. Hassan R, Morrow B, Thomas A et al (2019) Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc Natl Acad Sci USA 116(18):9008–9013. https://doi.org/10.1073/pnas.1821510116

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Irani S, Bidari-Zerehpoush F (2017) BRCA1/2 mutations in salivary pleomorphic adenoma and carcinoma-ex-pleomorphic adenoma. J Int Soc Prev Community Dent 7(Suppl 3):S155-s162. https://doi.org/10.4103/jispcd.JISPCD_184_17

    Article  PubMed  PubMed Central  Google Scholar 

  15. Jensen DE, Proctor M, Marquis ST et al (1998) BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16(9):1097–1112. https://doi.org/10.1038/sj.onc.1201861

    Article  CAS  PubMed  Google Scholar 

  16. Kakkar A, Guleria P, Madan K, Kumar R, Kumar S, Jain D (2019) Immunohistochemical assessment of BAP1 protein in mucoepidermoid carcinomas. Indian J Otolaryngol Head Neck Surg 71(1):33–37. https://doi.org/10.1007/s12070-018-1549-3

    Article  PubMed  Google Scholar 

  17. Kwon J, Lee D, Lee S-A (2023) BAP1 as a guardian of genome stability: implications in human cancer. Exp Mol Med. https://doi.org/10.1038/s12276-023-00979-1

    Article  PubMed  PubMed Central  Google Scholar 

  18. Laitman Y, Newberg J, Molho RB, Jin DX, Friedman E (2021) The spectrum of tumors harboring BAP1 gene alterations. Cancer Genet 256–257:31–35. https://doi.org/10.1016/j.cancergen.2021.03.007

    Article  CAS  PubMed  Google Scholar 

  19. Louie BH, Kurzrock R (2020) BAP1: Not just a BRCA1-associated protein. Cancer Treat Rev 90:102091. https://doi.org/10.1016/j.ctrv.2020.102091

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Masoomian B, Shields JA, Shields CL (2018) Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol 30(2):102–109. https://doi.org/10.1016/j.joco.2018.02.005

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nakajima Y, Kishimoto T, Nagai Y et al (2009) Expressions of androgen receptor and its co-regulators in carcinoma ex pleomorphic adenoma of salivary gland. Pathology 41(7):634–639. https://doi.org/10.3109/00313020903071595

    Article  CAS  PubMed  Google Scholar 

  22. Rai K, Pilarski R, Cebulla CM, Abdel-Rahman MH (2016) Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases. Clin Genet 89(3):285–294. https://doi.org/10.1111/cge.12630

    Article  CAS  PubMed  Google Scholar 

  23. Santana T, Pavel A, Martinek P et al (2019) Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications. Hum Pathol 93:37–47. https://doi.org/10.1016/j.humpath.2019.08.009

    Article  CAS  PubMed  Google Scholar 

  24. Shankar GM, Santagata S (2017) BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol 19(11):1447–1456. https://doi.org/10.1093/neuonc/nox094

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tondi-Resta I, Hobday SB, Gubbiotti MA et al (2023) Carcinoma ex pleomorphic adenomas: an institutional experience and literature review. Am J Clin Pathol. https://doi.org/10.1093/ajcp/aqac181

    Article  PubMed  Google Scholar 

  26. Wang K, McDermott JD, Schrock AB et al (2017) Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. Ann Oncol 28(4):748–753. https://doi.org/10.1093/annonc/mdw689

    Article  CAS  PubMed  Google Scholar 

  27. Wang K, Russell JS, McDermott JD et al (2016) Profiling of 149 salivary duct carcinomas, carcinoma ex pleomorphic adenomas, and adenocarcinomas, not otherwise specified reveals actionable genomic alterations. Clin Cancer Res 22(24):6061–6068. https://doi.org/10.1158/1078-0432.CCR-15-2568

    Article  CAS  PubMed  Google Scholar 

  28. Yu H, Pak H, Hammond-Martel I et al (2014) Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair. Proc Natl Acad Sci USA 111(1):285–290. https://doi.org/10.1073/pnas.1309085110

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was not supported by any funding.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA

    Eleonora Fiorletta Quiroga, Patricia R. Connor & J. Stephen Nix

  2. Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD, 21287, USA

    Lisa Rooper

  3. Department of Otolaryngology, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA

    Mauricio A. Moreno

Authors
  1. Eleonora Fiorletta Quiroga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia R. Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa Rooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mauricio A. Moreno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Stephen Nix
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EFQ, PRC, and JSN contributed to the pathology diagnosis, concept, acquisition/analysis of clinical data, and interpretation as well as wrote and revised the manuscript. LR contributed to the pathology diagnosis, critically reviewed the intellectual content of the work, and contributed to manuscript revision. MAM acquired clinical data, critically reviewed the intellectual content of the work, and contributed to the manuscript revision. All authors reviewed the manuscript.

Corresponding author

Correspondence to J. Stephen Nix.

Ethics declarations

Competing Interests

The authors have no competing interests or funding and declare that they have no conflicts of interest.

Research Involving Human Participants or Animals

This article does not contain any studies with human participants or animals performed by any of the authors as determined by the Institutional Review Board (UAMS).

Informed Consent

For this type of study (case report), informed consent is not required (IRB approved, UAMS).

Consent for Publication

Consent for publication was obtained for every individual person’s data included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Quiroga, E.F., Connor, P.R., Rooper, L. et al. Loss of BAP1 Protein Expression by Immunohistochemistry in the Salivary Duct Carcinoma Component of an Intracapsular Carcinoma ex Pleomorphic Adenoma of the Parotid Gland. Head and Neck Pathol 17, 851–854 (2023). https://doi.org/10.1007/s12105-023-01579-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12105-023-01579-1

Keywords

Search

Navigation